DK0814843T3 - Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug - Google Patents
Haptenbærerkonjugater til anvendelse i behandling af stofmisbrugInfo
- Publication number
- DK0814843T3 DK0814843T3 DK96910595T DK96910595T DK0814843T3 DK 0814843 T3 DK0814843 T3 DK 0814843T3 DK 96910595 T DK96910595 T DK 96910595T DK 96910595 T DK96910595 T DK 96910595T DK 0814843 T3 DK0814843 T3 DK 0814843T3
- Authority
- DK
- Denmark
- Prior art keywords
- hapten
- treatment
- carrier conjugates
- disclosed
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41497195A | 1995-03-31 | 1995-03-31 | |
US08/563,673 US5760184A (en) | 1995-03-31 | 1995-11-28 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
PCT/US1996/004189 WO1996030049A2 (en) | 1995-03-31 | 1996-03-27 | Hapten-carrier conjugates for use in drug-abuse therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0814843T3 true DK0814843T3 (da) | 2004-03-29 |
Family
ID=27022809
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96910595T DK0814843T3 (da) | 1995-03-31 | 1996-03-27 | Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug |
DK03008324T DK1329226T3 (da) | 1995-03-31 | 1996-03-27 | Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03008324T DK1329226T3 (da) | 1995-03-31 | 1996-03-27 | Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug |
Country Status (10)
Country | Link |
---|---|
US (1) | US6054127A (da) |
EP (1) | EP0814843B1 (da) |
AT (2) | ATE362380T1 (da) |
AU (1) | AU5374996A (da) |
CA (1) | CA2216658C (da) |
DE (2) | DE69630877T2 (da) |
DK (2) | DK0814843T3 (da) |
ES (2) | ES2287379T3 (da) |
PT (1) | PT814843E (da) |
WO (1) | WO1996030049A2 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773003A (en) * | 1995-03-31 | 1998-06-30 | Immulogic, Inc. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US5817770A (en) | 1997-03-21 | 1998-10-06 | Drug Abuse Sciences, Inc. | Cocaethylene immunogens and antibodies |
SE9801923D0 (sv) * | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
CA2403252A1 (en) | 2000-03-15 | 2001-09-20 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
AU2002226055A1 (en) * | 2000-12-07 | 2002-06-18 | The Scripps Research Institute | Cocaine haptens |
EP1523334A2 (en) * | 2002-07-18 | 2005-04-20 | Cytos Biotechnology AG | Hapten-carrier conjugates and uses thereof |
US7220842B2 (en) * | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
US20060024768A1 (en) * | 2004-07-29 | 2006-02-02 | Saladax Biomedical, Inc. | Taxol immunoassay |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
EP2214672B1 (en) * | 2007-10-18 | 2012-10-17 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
FR2952935B1 (fr) * | 2009-11-20 | 2011-12-02 | Sanofi Aventis | Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
CN108409749B (zh) * | 2018-01-30 | 2019-09-06 | 中国农业科学院蜜蜂研究所 | 钩吻素己半抗原和全抗原及其制备方法与应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4375414A (en) * | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
US3766162A (en) * | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US3888886A (en) * | 1972-06-08 | 1975-06-10 | Mobil Oil Corp | Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst |
US4045420A (en) * | 1973-05-29 | 1977-08-30 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof |
US4197237A (en) * | 1973-06-01 | 1980-04-08 | Syva Company | Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof |
US4207307A (en) * | 1977-01-21 | 1980-06-10 | Research Corporation | Simultaneous immunoassay of multiple antigens and assay for cocaine metabolites |
SU792869A1 (ru) * | 1979-03-30 | 1982-03-30 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Способ получени конъюгированных антигенов барбитурова кислота-иммуногенный носитель |
US4376825A (en) * | 1979-05-07 | 1983-03-15 | Syva Company | Enzyme amplification compounds for assays for androgens |
US4666837A (en) * | 1982-05-24 | 1987-05-19 | Smithkline-Rit | DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits |
SU1123704A1 (ru) * | 1983-04-08 | 1984-11-15 | Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений | Способ получени конъюгированных антигенов |
US5019384A (en) * | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US4791067A (en) * | 1987-06-25 | 1988-12-13 | Fisher Scientific Co. | Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent |
DE3884731D1 (de) * | 1987-10-09 | 1993-11-11 | Ube Industries | Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin. |
AU634153B2 (en) * | 1988-02-01 | 1993-02-18 | Wyeth Holdings Corporation | T-cell epitope as carriers molecule for conjugate vaccines |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
US5026827A (en) * | 1988-09-02 | 1991-06-25 | Matsushita Electric Industrial Co., Ltd. | Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine |
US5268276A (en) * | 1988-09-16 | 1993-12-07 | Jan Holmgren | Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides |
EP0363041A1 (en) * | 1988-09-21 | 1990-04-11 | Ube Industries, Ltd. | Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine |
ATE154135T1 (de) * | 1989-03-10 | 1997-06-15 | Hoffmann La Roche | Reagenzien zum nachweis von drogen |
GB8924438D0 (en) * | 1989-10-31 | 1989-12-20 | Hoffmann La Roche | Vaccine composition |
US5096838A (en) * | 1989-11-27 | 1992-03-17 | Abbott Laboratories | Barbiturate assay compositions and methods |
CH678394A5 (da) * | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
JPH04182499A (ja) * | 1990-11-14 | 1992-06-30 | Matsushita Electric Ind Co Ltd | エクゴニン・タンパク質コンジュゲート及びその誘導体 |
US5233042A (en) * | 1991-12-16 | 1993-08-03 | Biosite Diagnostics, Inc. | Cocaine derivatives |
US5283066A (en) * | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
US5302715A (en) * | 1992-04-06 | 1994-04-12 | Biosite Diagnostics, Inc. | Benzodiazepine derivatives |
WO1993023076A1 (en) * | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
DE69332637T2 (de) * | 1993-03-04 | 2003-10-23 | Matsushita Electric Ind Co Ltd | Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers |
EP0724588B1 (en) * | 1993-09-17 | 1999-11-10 | Smithkline Beecham Corporation | Drug binding protein |
WO1995027786A1 (en) * | 1994-04-08 | 1995-10-19 | Immulogic Pharmaceutical Corporation | Pharmaceutical formulations for treating japanese cedar pollen allergy |
-
1996
- 1996-03-27 WO PCT/US1996/004189 patent/WO1996030049A2/en active IP Right Grant
- 1996-03-27 PT PT96910595T patent/PT814843E/pt unknown
- 1996-03-27 DE DE69630877T patent/DE69630877T2/de not_active Expired - Lifetime
- 1996-03-27 AT AT03008324T patent/ATE362380T1/de active
- 1996-03-27 AU AU53749/96A patent/AU5374996A/en not_active Abandoned
- 1996-03-27 DK DK96910595T patent/DK0814843T3/da active
- 1996-03-27 DK DK03008324T patent/DK1329226T3/da active
- 1996-03-27 ES ES03008324T patent/ES2287379T3/es not_active Expired - Lifetime
- 1996-03-27 ES ES96910595T patent/ES2210356T3/es not_active Expired - Lifetime
- 1996-03-27 AT AT96910595T patent/ATE254930T1/de active
- 1996-03-27 DE DE69637089T patent/DE69637089T2/de not_active Expired - Lifetime
- 1996-03-27 CA CA002216658A patent/CA2216658C/en not_active Expired - Fee Related
- 1996-03-27 EP EP96910595A patent/EP0814843B1/en not_active Expired - Lifetime
-
1997
- 1997-06-27 US US08/884,497 patent/US6054127A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6054127A (en) | 2000-04-25 |
ATE254930T1 (de) | 2003-12-15 |
AU5374996A (en) | 1996-10-16 |
EP0814843A2 (en) | 1998-01-07 |
PT814843E (pt) | 2004-04-30 |
EP0814843B1 (en) | 2003-11-26 |
WO1996030049A2 (en) | 1996-10-03 |
DE69630877T2 (de) | 2004-11-11 |
CA2216658C (en) | 2008-05-13 |
ES2210356T3 (es) | 2004-07-01 |
DE69637089T2 (de) | 2008-01-17 |
DE69637089D1 (de) | 2007-06-28 |
CA2216658A1 (en) | 1996-10-03 |
ES2287379T3 (es) | 2007-12-16 |
WO1996030049A3 (en) | 1997-03-06 |
ATE362380T1 (de) | 2007-06-15 |
DK1329226T3 (da) | 2007-09-24 |
DE69630877D1 (de) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1024834T3 (da) | Hapten bærer konjugater til anvendelse ved stofmisbrugsterapi og fremgangsmåder til fremstilling af samme | |
DK0814843T3 (da) | Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug | |
EP1329226A3 (en) | Hapten-Carrier Conjugates for use in Drug Abuse Therapy | |
IL143474A0 (en) | Haptene-carrier conjugates and vaccines containing the same | |
WO2004009116A3 (en) | Hapten-carrier conjugates comprising virus like particles and uses thereof | |
DE59107814D1 (de) | Impfstoff gegen drogen | |
WO2003061595A3 (en) | Antibodies against and compositions containing new amphetamine derivatives | |
DE3787477D1 (de) | Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung. | |
NO985791L (no) | Enhet for transdermal administrering av trimegeston, fremgangsmÕte for fremstilling av enheten og anvendelse av denne som medikament | |
ATE258804T1 (de) | Verfahren zur verabreichung von wachstumsfaktoren |